India, Feb. 27 -- Glenmark Pharmaceuticals announced on Thursday that it has introduced a generic version of the Epinephrine injection multiple-dose vial in the U.S., qualifying for 180 days of Competitive Generic Therapy (CGT) exclusivity.
In a statement, the company said that its U.S. subsidiary, Glenmark Pharmaceuticals Inc., has launched the Epinephrine Injection USP in a strength of 10 mg/10 mL (1 mg/mL) multiple-dose vial.
Glenmark further stated that its Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose vial is both bioequivalent and therapeutically equivalent to the reference-listed drug manufactured by BPI Labs, LLC.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....